Angiosarcomas Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Sarcoma is a group of soft tissue tumors and a rare and clinically variable type of cancer that originates due to the transformation of mesenchymal cells. Angiosarcomas mainly occurs in the breast, bone, skin, soft tissues, and spleen. It grows in the cells of blood vessels and spreads into various parts of the body that affects the normal activity. This type of tumor has rapidly multiplying cancerous cells, which originated from mesenchymal or endothelial source. Such tumors typically appears on skin and face and while high growth of these tumors they can increases the risk of mortality. The severity and spreading area of the disease is projected to be one of the major cause that will support growth of the angiosarcomas treatment market over the forecast period.

There are various types of angiosarcomas such as Epithelioid Angiosarcoma, Cardiac Angiosarcoma, Hepatic Angiosarcoma and Cutaneous Angiosarcoma. As per the stats of Know Cancer (this institute known for connecting cancer infected people to empower and educate them about cancer) cutaneous angiosarcomas contributes to the maximum of angiosarcomas cases, which is around 60% followed by angiosarcomas found in deep tissue and in breast tissue contributes around 35% in overall cases. Skin lesions, bone pain, fatigue, anemia and heart pain are some symptoms of angiosarcomas, though these vary according to location of angiosarcomas.

Fill the form for an exclusive sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/396

The treatment options available for angiosarcomas are surgery, chemotherapy and radiotherapy. Furthermore, according to the National Cancer Institute (NCI), the survival rate is around 5 year after diagnosis which is found in 50% of the people having angiosarcomas. The people who respond to treatment and show some recovery in first 5 years after diagnosis of angiosarcomas, have more chances of survival. According to the data published by NCI in 2014, based on 5 years study the survival rate for sarcoma was pegged at 90% those in first stage, 81% at second stage, 56% during third stage and during fourth stage there is no survival rate available. Also, some diagnostics tests such as CT, PET, MRI scan and biopsy test for the effective diagnosis of angiosarcomas.

As per results of a study by Coherent Market Insights, in August 2015, the incidence rate for this disease is very low, with angiosarcomas contributing 1-2% towards sarcoma cases. Rapid surge in number of cancer cases worldwide inadvertently creates a highly conducive environment for growth of the angiosarcomas treatment market.

As per the stats published by European Medicines Agency in January, there are around 3.5 in 10,000 people affected by angiosarcomas in Europe, in 2016. While in U.S. as per the stats of Know Cancer, angiosarcomas account for only 0.7% of cancer cases which makes it very rare type of cancer.

Angiosarcomas treatment market taxonomy:

Global Market by location of Instigation

Hemangiosarcoma
Lymphangiosarcoma
Global Market by Type of Treatment

Surgery
Chemotherapy
Radiotherapy
Global Market by Geography

North America
Europe
APAC
Latin America
Middle East
Africa
Expected rise in prevalence of angiosarcomas disease and increase in research and development into cancer treatment drugs are the major factors driving the growth of angiosarcomas treatment market

As the major research and development activities in the area of cancer are mostly performed in North America region, it holds the major market share of angiosarcomas treatment market followed by Europe backboned by increased healthcare infrastructure development, affordability of drugs, developed treatment options and high awareness about available treatments.

Increase in number of cancer cases and growing awareness regarding the treatments in emerging economies are expected to contribute majorly in the growth of angiosarcomas treatment market. Furthermore, growth in per capita income is projected to support the high health care spending by the population, which in turn is expected to favor the growth in angiosarcomas treatment industry in the near future.

As the disease is rare, only few organizations are investing in research and development and high cost of the drugs are the growth restraining factors of market in angiosarcomas treatment. However, considering the projected increase in incidence of the disease in the near future, the market is expected to witness the entry of various new players.

Request for table of content : https://www.coherentmarketinsights.com/ongoing-insight/toc/396

Major companies involved in the angiosarcomas treatment market include Genentech, Inc., Pfizer Inc., Janssen Global Services, LLC, Bayer AG, Sanofi, Amgen Inc., also some innovative leading drugs include irinotecan, sildenafil, bevacizumab, BAY43-9006, and SU11248.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
E-mail:sales@coherentmarketinsights.com
Website:https://www.coherentmarketinsights.com

This release was published on openPR.